GLP1R and type 2 diabetes mellitus: However, the Harmony Outcomes trial (n = 10,793), which randomized patients with T2DM and high CVD risk to a drug regimen of the GLP-1 RA albiglutide or a placebo [103], noticed a significant reduction of 22% in the first occurrence of cardiovascular-related death, myocardial infarction or stroke [101].